AIM ImmunoTech Inc. (AIM)
| Previous close | 0.4769 |
| Open | 0.4823 |
| Bid | 0.4820 x 800 |
| Ask | 0.4899 x 800 |
| Day's range | 0.4800 - 0.4996 |
| 52-week range | 0.3200 - 0.7500 |
| Volume | |
| Avg. volume | 234,143 |
| Market cap | 24.477M |
| Beta (5Y monthly) | -0.15 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
OCALA, Fla., April 18, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced the next CEO Corner segment has been published on the Company’s website. For the CEO Corner segment, Thomas Equels, Chief Executive Officer of AIM ImmunoTech, gave an overview of Locally Advanced Pancreatic Adenocarcinoma and the unmet need. The CEO Corner segment is now available here. About AIM ImmunoTech Inc. AIM ImmunoTech Inc. is an immuno-pharma company focused
- GlobeNewswire
AIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its ME/CFS and Long COVID Programs
Charles W. Lapp, MD Charles W. Lapp, MD OCALA, Fla., April 15, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”) today announced that Charles Lapp, MD, is joining the company to help lead its efforts to develop Ampligen (rintatolimod) as a potential treatment for Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and Long COVID. Dr. Lapp has played a key role in AIM’s long-standing AMP-511 Expanded Access Program for the treatment of ME/CFS and Long COVID, having
- GlobeNewswire
AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer
Robert Edwards, MD, Chair of the Department of Obstetrics, Gynecology & Reproductive Sciences and Co-Director of Gynecologic Oncology Research at Magee-Womens Hospital of UPMC Robert Edwards, MD, Chair of the Department of Obstetrics, Gynecology & Reproductive Sciences and Co-Director of Gynecologic Oncology Research at Magee-Womens Hospital of UPMC OCALA, Fla., April 10, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”) today announced top-line interim data indicating th
